Key Highlights

  • Revenue was USD 47,628, against an estimate of USD 2.04 million.
  • Loss per share was USD 0.18, against an estimate of a USD 0.13 loss.
  • Net loss narrowed to USD 3.16 million from USD 3.56 million.
  • Cash and cash equivalents were USD 11.53 million at September 30, 2026.

Daré Bioscience (NASDAQ:DARE) trimmed its third quarter 2026 net loss to USD 3.16 million, from USD 3.56 million a year earlier, but Revenue came in far under the estimate. Revenue of USD 47,628 compares with USD 2,262 in the prior-year quarter and an estimate of USD 2.04 million, and it consisted of Research and Development services and other revenue. Basic and diluted loss per common share was USD 0.18, compared with USD 0.28, against an estimate of a USD 0.13 loss.

Costs and the Operating Loss

Cost of revenues was USD 180,479, with none reported in the prior-year quarter. Selling, general and administrative expenses were USD 2.64 million, compared with USD 2.50 million, while research and development expenses dropped to USD 318,906 from USD 1.18 million. Total operating expenses were USD 2.96 million, compared with USD 3.67 million, and the loss from operations was USD 3.09 million, compared with USD 3.67 million.

Other expense was USD 65,791, compared with other income of USD 109,382. Weighted average shares outstanding, basic and diluted, were 17,421,580, compared with 12,755,112. The comprehensive loss was USD 3.15 million, including a foreign currency translation adjustment of USD 6,586.

Nine Months to September 30

For the nine months ended September 30, 2026, revenue was USD 387,629, compared with USD 6,517, and cost of revenues was USD 742,693. Selling, general and administrative expenses were USD 7.48 million, compared with USD 7.19 million, and research and development expenses were USD 1.22 million, compared with USD 4.90 million.

Total operating expenses were USD 8.70 million, compared with USD 12.09 million, and the loss from operations was USD 9.06 million, compared with USD 12.08 million. The net loss was USD 9.14 million, compared with USD 11.96 million, and loss per share was USD 0.59, compared with USD 1.18. Weighted average shares outstanding were 15,622,034, compared with 10,143,078.

Cash, Grants and Going Concern Doubt

Cash and cash equivalents were USD 11.53 million at September 30, 2026, compared with USD 24.71 million at December 31, 2025. The filing says most of that cash is grant money received from a private foundation, which can go only toward the direct costs of the funded projects, plus an indirect cost allowance.

Total Assets were USD 22.10 million, compared with USD 32.47 million, and total current liabilities were USD 13.71 million, compared with USD 23.69 million. Total liabilities were USD 19.76 million, compared with USD 29.63 million, and included a Liability tied to the sale of future royalties. Additional paid-in Capital was USD 200.54 million, compared with USD 191.95 million.

The filing discloses substantial doubt about the company's going concern status within 12 months of the issuance date of the financial statements.